TrumpRx and the $50 Medicare Bridge: Who Actually Qualifies in 2026 (and Who Doesn't)

In 2026 two separate programs changed what a GLP-1 can cost if you pay without commercial insurance. One is the federal TrumpRx direct-purchase channel. The other is a $50-a-month Medicare bridge from the manufacturers. They get written about interchangeably, which is a problem, because they cover different drugs, different people, and different time windows — and if you assume one applies to you when the other does, you budget for a price you will never actually be offered.

I went through the current program terms for both. Here is where the eligibility lines actually fall.

TrumpRx is a self-pay channel, not an insurance benefit

TrumpRx routes you to buy directly from the manufacturer at a set self-pay price. It does not run through your insurance, and it is not a discount card you stack on top of a copay. It is the cash price, full stop.

As of mid-2026 the direct self-pay figures that channel surfaces are roughly:

• The injectable pen at about $199 a month
• The oral pill (semaglutide in tablet form, approved by the FDA in December 2025) at about $149 a month
• Zepbound (tirzepatide) starting around $299 a month at the 2.5 mg starting dose

Two things to hold onto. First, the injectable figures are introductory on the Novo Nordisk side — the widely quoted low price covers only the first fills, and the standing self-pay price after that is higher (around $349 a month for maintenance Wegovy, more at the top doses). Second, the Zepbound figure climbs steeply with dose. The 2.5 mg starter is a starting dose nobody stays on; the maintenance doses most people titrate up to are priced far higher, and part of that price is conditional on refilling inside a 45-day window.

So "GLP-1s are $199 on TrumpRx" is true the way "flights are $49" is true. It is a real entry price attached to a specific dose and a specific fill number, not the number you pay to stay on the drug.

The $50 Medicare bridge covers fewer drugs than people think

Separately, manufacturers introduced a Medicare bridge priced at $50 a month, running from July 2026 through December 2027. This one exists because Medicare Part D does not cover GLP-1s prescribed purely for weight loss, and copay cards are legally barred on Medicare — so people on Medicare had no manufacturer help at all. The bridge fills that gap, temporarily.

But it does not cover every GLP-1. Based on the program terms, the $50 bridge applies to:

• Wegovy
• Zepbound (the KwikPen)
• The oral semaglutide product

And it does not apply to Ozempic or Mounjaro — the versions labeled for type 2 diabetes. That distinction trips people up constantly, because Ozempic and Wegovy are the same molecule (semaglutide) and Mounjaro and Zepbound are the same molecule (tirzepatide). The bridge follows the label, not the molecule. If your prescription is written for Ozempic, the $50 Wegovy bridge is not yours, even though the drug inside is identical.

If you want the full map of which brand is which molecule and why that difference decides your price and your coverage, I keep a plain-language version of it here: the two-molecule, four-brand GLP-1 map.

The Medicare-vs-copay-card wall is the thing to understand first

The reason a special Medicare program had to exist at all is worth stating plainly, because it is the single most expensive misunderstanding in this space.

Manufacturer copay cards — the ones that drop a commercially insured patient's cost to as little as $25 a month — are barred by federal anti-kickback rules for anyone on Medicare, Medicaid, or TRICARE. This is not the manufacturer being stingy; it is the law. If you move onto Medicare and try to keep using the copay card you had on commercial insurance, it stops working, and the cliff can be thousands of dollars a year.

That is the gap the $50 bridge is designed to soften — but only for the drugs listed above, and only through the end of 2027. After that, unless it is renewed, the cliff returns.

I wrote a fuller breakdown of how copay cards and insurance interact, and where the traps are, here.

Who each program is actually for

Read against the terms, the honest summary is:

TrumpRx self-pay is for someone with no insurance coverage for the drug — either uninsured, or insured with a plan that excludes weight-loss GLP-1s — who is willing to pay cash and wants the lowest cash entry point. Its best feature is the oral pill at ~$149, because a pill has no cold-chain and no needles. Its trap is assuming the introductory injectable price is your forever price.

The $50 Medicare bridge is for someone on Medicare, prescribed Wegovy, Zepbound, or oral semaglutide, between now and December 2027. It is not for Ozempic or Mounjaro, and it is not permanent.

Neither helps the largest group — people with commercial insurance whose plan simply excludes GLP-1s for weight loss. For them the lever is a coverage appeal or a formulary exception, not a self-pay program.

Before you enroll in either, check three things

1. Which drug is on your actual prescription — brand name, not molecule. The bridge and several savings programs key off the label.
2. Your dose, and what it will cost at maintenance — not the starter price. Ask specifically what the price becomes after the introductory fills, and whether any discounted maintenance price depends on refilling within a set number of days.
3. Your insurance type — commercial, Medicare, Medicaid, or none. This one fact determines which of these programs are even legal for you to use.

The current direct-purchase self-pay details, kept up to date as the manufacturers change them, are collected here: what TrumpRx actually offers for uninsured buyers. And the Medicare-specific picture — what Part D does and doesn't cover, and where the bridge fits — is here.

These programs are genuinely useful. They are also written to be quoted at their lowest number. The difference between the quoted number and your number is the whole game, and it lives entirely in the terms.

Prices and program dates verified July 2026 against manufacturer program terms; re-check before enrolling, as these change without notice.